In a patient on hemodialysis with an estimated glomerular filtration rate less than 15 mL/min/1.73 m², what glucose‑lowering therapy should be initiated?

Glucose-Lowering Therapy for Hemodialysis Patients with eGFR <15

For patients on hemodialysis with eGFR <15 mL/min/1.73 m², initiate insulin as the primary glucose-lowering therapy, with GLP-1 receptor agonists (dulaglutide, liraglutide, or semaglutide) as preferred alternatives if glycemic targets are not met or if cardiovascular benefits are desired. 1, 2

Primary Treatment Approach

Insulin Therapy (First-Line)

• Insulin remains the only universally safe and effective option at this stage of kidney disease 1
• Initiate and titrate conservatively to avoid hypoglycemia, as insulin clearance is significantly reduced in advanced CKD 1
• Doses typically need to be reduced by up to 50% compared to earlier CKD stages due to decreased insulin clearance 3
• Monitor blood glucose closely during and after dialysis sessions, as hemodialysis removes glucose from circulation and improves insulin sensitivity 4

Critical caveat: Hypoglycemia risk is substantially elevated in hemodialysis patients, accounting for up to 3.6% of ESRD-related admissions with 30% mortality rates when it occurs during hospitalization 3. This makes conservative dosing essential.

Alternative/Additional Agents

GLP-1 Receptor Agonists (Preferred Add-On)

GLP-1 receptor agonists are the preferred second-line agents for patients on dialysis who need additional glycemic control beyond insulin 1, 2:

• Dulaglutide: No dose adjustment required; can be used with eGFR >15 mL/min/1.73 m² 2
• Liraglutide: No dose adjustment required; limited data but safe in severe CKD 2
• Semaglutide (injection or oral): No dose adjustment required; limited data in severe CKD 2

Key advantages in this population:

• Retain glucose-lowering potency even at eGFR <15 and in dialysis patients 1
• Provide cardiovascular benefits (MACE reduction was greater in patients with eGFR <60 than ≥60) 1
• Do not cause hypoglycemia when used alone 2
• Reduce albuminuria and slow eGFR decline 1

Important considerations:

• Nausea and vomiting occur in 15-20% of patients with advanced CKD but usually resolve with slow titration 1
• Use caution in patients at risk for malnutrition due to weight loss effects 1
• Can be beneficial for obese patients needing weight loss for transplant eligibility 1

DPP-4 Inhibitors (Alternative Option)

If GLP-1 receptor agonists are not tolerated or available 1:

• Linagliptin: No dose adjustment required 1
• Alogliptin: Maximum 6.25 mg daily 1
• Sitagliptin: Maximum 25 mg once daily 1
• Saxagliptin: Maximum 2.5 mg daily 1

These provide safe glycemic control without hypoglycemia risk but lack the cardiovascular and kidney benefits of GLP-1 receptor agonists 1.

Thiazolidinediones (Limited Role)

• Pioglitazone: No dose adjustment required 1
• Improves insulin resistance (common in advanced CKD) and retains antihyperglycemic effects 1
• Major concern: Fluid retention and heart failure risk require careful monitoring 1

Contraindicated Medications

Metformin: Absolutely contraindicated with eGFR <30 and in dialysis patients 1, 2

Avoid or use with extreme caution:

• Glyburide: Not recommended 1
• Acarbose and Miglitol: Not recommended with eGFR <15 1
• Exenatide: Not recommended with eGFR <15 2
• Lixisenatide: Not recommended with eGFR <15 2

SGLT2 inhibitors: While canagliflozin and dapagliflozin can be continued if previously initiated and tolerated for cardiovascular/kidney benefits until dialysis, they have minimal glucose-lowering efficacy at this eGFR level and should not be newly initiated for glycemic control 1

Practical Algorithm

1. Start with insulin using conservative dosing (reduce typical doses by ~50%)
2. If glycemic targets not met or cardiovascular disease present: Add GLP-1 receptor agonist (dulaglutide, liraglutide, or semaglutide preferred for CV benefits) 1, 2
3. If GLP-1 receptor agonist not tolerated: Consider DPP-4 inhibitor (linagliptin preferred—no dose adjustment) 1
4. Monitor closely: Blood glucose during dialysis sessions, adjust insulin doses on dialysis vs. non-dialysis days 4
5. Target less stringent glycemic goals: HbA1c 7-8.5% (53-69 mmol/mol) and average blood glucose 150-200 mg/dL to minimize hypoglycemia risk 3

Common pitfall: Using standard insulin doses without accounting for reduced clearance leads to severe hypoglycemia. Always start low and titrate slowly in hemodialysis patients.